SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,805,873.7130931 in circulation. The last known price of Litecoin is 52.00804602 USD and is down -0.75 over the last 24 hours. It is currently trading on 1567 active market(s) with $117,565,973.29 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoins sharp pullback and weak price action are driving technical discussion, with traders watching whether support holds. Some are accumulating on the dip and anticipating a reversal, while others see bearish momentum and continued underperformance.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is drawing attention amid sharp swings in South Korean equities, with traders tying the selloff and rebounds to volatility in AI memory-chip leaders Samsung and SK Hynix and the broader semiconductor trade. The community is split between looking for a recovery as memory shares bounce and expecting more downside from leveraged selling and continued AI-sector weakness.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline: traders are watching for further REGAIN glioblastoma data, updates from the completed-enrollment IMPACT pancreatic trial, ReSTART results, and a possible FDA IDE for the Keytruda combination. The community is broadly bullish on the upcoming milestones and recent share-price strength, though some are waiting for confirmed updates rather than speculating about the next announcement.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on encouraging early zugo-cel results in autoimmune diseases, with traders highlighting responses in systemic sclerosis and myositis and the therapys reported tolerability. Bulls view the data as support for an off-the-shelf CD19 CAR-T approach, while others caution that the patient groups are small and longer follow-up is needed to assess durability and safety.

Flutter Entertainment Plc engages in the business of online betting and gaming. It operates through the following segments: UK and Ireland, Australia, International, and US. The UK and Ireland segment includes the operations of Sky Betting and Gaming, Paddy Power, Betfair, and tombola. The Australia segment focuses on sports betting services provided to Australian customers online. The International segment relates to poker, casino, rummy, lottery, and sports betting. The US segment includes sports betting, daily fantasy sports, and gaming services. The company was founded in 1988 and is headquartered in New York, NY.

Flutter Entertainment Plc

Flutters Q3 results missed expectations and the company lowered its 2026 outlook, while a temporary buyback pause added to investor concerns about profitability. Traders are debating the setback against a share-price rebound, with marketing costs and competition from prediction markets still central to the outlook.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Dows quarterly results and stronger outlook are driving discussion, with traders weighing the earnings beat against concerns that higher chemical pricesnot stronger underlying volumesare doing much of the work. Reactions are mixed, as some see improving conditions while others question the stocks response and remain cautious about demand and the broader market.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Traders are focused on the FDA decision for povetacicept in IgA nephropathy, with positive Phase 3 RAINIER results and detailed published data fueling hopes it could become a new kidney-disease growth driver. The community is broadly optimistic, though claims that approval is inevitable or that a news leak is behind the move remain speculation; reactions to Vertexs Q3 results are more mixed.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Discussion is fragmented, with the most common theme being swings in the broader Nasdaq and tech market: traders debate whether selloffs will deepen or give way to a rebound. Company-specific posts also point to recent quarterly results and Nasdaqs planned extended-hours trading, but neither clearly dominates the conversation.

Wormhole (W) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Wormhole has a current supply of 10,000,000,000 with 6,739,085,180 in circulation. The last known price of Wormhole is 0.01098266 USD and is down -2.87 over the last 24 hours. It is currently trading on 429 active market(s) with $95,009,446.02 traded over the last 24 hours. More information can be found at https://wormhole.com.

Wormhole

Wormholes integration with Ripple/XRPL and its cross-chain interoperability role are drawing attention, with traders betting on broader adoption and tokenization use cases. Bullish calls contrast with complaints about weak price action and concerns over token unlocks and supply pressure.

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcepts Q3 report and rapid Lifyorli launch growth are drawing attention, though the shares remain weak after a steep pullback. Traders debate whether unchanged full-year guidance and competition from Genmabs Rina-S temper the outlook, while watching the upcoming FDA decision on relacorilant for Cushings syndrome.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PATH automating a task only saves money if the task was costing money that actually leaves. seems like when the salary stays and the bot fee is added, finance counts two costs, not a saving

StockTwits Web

UiPath Inc

 automating a task only saves money if the task was costing money that actually leaves. seems like when the salary stays and the bot fee is added, finance counts two costs, not a saving

Clam Clamwell

@thatsolardude365 If I’m a construction worker and I buy a nail gun vs using a hammer.. don’t you think that will lead to a better business outcome?

StockTwits for iOS

 If I’m a construction worker and I buy a nail gun vs using a hammer.. don’t you think that will lead to a better business outcome?